Bionyra Pharma

Visit Website

Clinical-stage company developing half-life-extended mono and multispecific antibodies for immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and IBD; pipeline includes anti-IL-25, anti-TL1A, and a TL1A×IL-23 bispecific.

Headquarters

Paris, France / Boston, USA

Year Founded

2025

Founders

Frédéric Marrache, Sofinnova Partners

Country

France

Financial Information

Funding Stage

Series A

Recent Funding

$165M

Funding By

Jeito Capital, Sofinnova Partners, Arkin Bio, Sanofi Ventures

Core Technology

Half-life-extended mono and multispecific antibodies (IL-25, TL1A, TL1A×IL-23)

Product Type

Drug

Pipeline Stage (Very Important)

Phase I

Regulatory Status

IND Filed: Yes
FDA/EMA Status: Clinical
Clinical Trial Registration: Phase 1 BYN-001, BYN-002, BYN-003
Patents / IP Status: Licensed (ex-China rights from NovaRock and TrueLab)

Partnerships

Pharma Collaborations

Sanofi Ventures (investor); licensed from NovaRock and TrueLab

Academic / Hospital Tie-ups

None disclosed

CRO/CDMO Partnerships

None disclosed

Market & Differentiation

Clinical I&I pipeline combining validated targets with half-life extension and bispecifics